Filing summary
Filing identity and period: The supplied filing is Isoray, Inc.’s Form 10-Q for the quarter ended September 30, 2019 (the first quarter of its fiscal 2020), filed November 13, 2019. This does not match the request metadata identifying Perspective Therapeutics, Inc. and 2019 Q1; verify the issuer and period before relying on this summary.
Business context and financial results
Isoray manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. Unless otherwise noted, amounts below are in thousands of dollars; quarterly comparisons are with the quarter ended September 30, 2018.
| Metric | Quarter ended Sep. 30, 2019 | Prior-year quarter | Change / context |
|---|---|---|---|
| Net sales | $2,315 | $1,562 | Up 48%; prostate brachytherapy represented 90% of sales |
| Cost of sales | $1,079 | $1,038 | Up 4% |
| Gross profit / margin | $1,236 / 53% | $524 / 34% | Gross profit up 136% |
| Operating expenses | $2,072 | $2,042 | Includes a $73 gain from revising the asset retirement obligation estimate |
| Operating loss | $(836) | $(1,518) | Loss narrowed |
| Net loss | $(816) | $(1,508) | Loss per share: $(0.01), versus $(0.02) |
| Operating cash flow | $(653) | $(1,612) | Cash used decreased |
| Investing cash flow | $(98) | $(6,289) | Prior-year period included significant certificate-of-deposit activity |
Financial position and liquidity
- At September 30, 2019, cash and cash equivalents were $4.575 million (versus $5.326 million at June 30); cash, cash equivalents and restricted cash totaled $4.756 million.
- Working capital was $5.140 million and the current ratio was 4.09. Total assets were $10.124 million; shareholders’ equity was $6.955 million.
- The company reported no long-term debt. Total liabilities were $3.169 million, including $1.173 million of operating lease liabilities recognized upon adoption of the new lease standard.
- Cash decreased by $751,000 during the quarter; there were no financing cash flows. Capital expenditures included production automation.
Changes, outlook, and risks
- Management attributed sales growth to new accounts, higher orders from existing customers, and limited-market-release sales of the Blu Build loader. Lower isotope unit costs and more efficient isotope use supported the substantial gross-margin improvement.
- Research and development expense fell, partly because of a grant-related accrual reversal and reduced Blu Build development spending. Management expects R&D expense to return toward historical levels; the filing cautions that future projects may increase costs.
- Management’s fiscal 2020 plan assumed at least 25% annual revenue growth, which it said the company exceeded in this quarter. Subject to achieving continuing growth and avoiding extraordinary expenses, management estimated cash-flow break-even in three to four years; it gave no assurance that growth would continue.
- Management said additional financing may be needed and could dilute existing shareholders. The company stated it might need to raise capital within nine to twelve months to maintain its NYSE American listing, assuming projected expenses and revenue.
- Customer concentration is material: approximately 48% of quarterly revenue came from five customers, and approximately 24% came from one physician-group-associated customer group. Loss of a major customer could materially affect revenue.
- Cesium-131 supply depends on Russian sources. One historic supplier’s reactor was scheduled to be shut down into 2020, and the filing notes uncertainty around future supply arrangements and processing of the company’s enriched barium inventory.
- Other brachytherapy applications have uncertain reimbursement and potentially volatile adoption. GammaTile-related revenue was nominal in the quarter; expanded FDA indication was under review, with no assurance of clearance or sales growth.
- The production-facility lease was extended, and the company recognized an estimated $73,000 gain after revising its asset retirement obligation. No material legal proceedings or off-balance-sheet arrangements were reported; management said disclosure controls were effective.
Important facts to verify
- Confirm that Isoray, Inc. and the September 30, 2019 quarter—not Perspective Therapeutics or another period—are the intended filing.
- Check actual revenue growth, cash burn, and whether the company achieved its fiscal 2020 growth targets in later filings.
- Review cash runway, financing needs, and NYSE American listing status, including any dilution from future capital raises or warrant exercises.
- Assess customer concentration and the continuity, terms, and operational reliability of Cesium-131 supply.
- Verify subsequent developments in GammaTile’s FDA review, reimbursement, and commercial uptake.